title: Rapid improvement of life-threatening capillary leak syndrome after stem cell transplantation by bevacizumab.
authors.forename: Hiromasa
authors.initials: H
authors.lastname: Yabe
authors.forename: Miharu
authors.initials: M
authors.lastname: Yabe
authors.forename: Takashi
authors.initials: T
authors.lastname: Koike
authors.forename: Takashi
authors.initials: T
authors.lastname: Shimizu
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Morimoto
authors.forename: Shunichi
authors.initials: S
authors.lastname: Kato
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D019559:Capillary Leak Syndrome / Q000188:drug therapy* / Q000209:etiology; D002648:Child; D006086:Graft vs Host Disease / Q000209:etiology; D006801:Humans; D008297:Male; D010996:Pleural Effusion / Q000188:drug therapy / Q000209:etiology; D054038:Posterior Leukoencephalopathy Syndrome / Q000188:drug therapy* / Q000209:etiology; D012074:Remission Induction; D014184:Transplantation, Homologous; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab